Prediction of response in cancer immunotherapy

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 639-647

  Characiejus, Dainius ^a   Jacobs, John J L ^b   Pašukoniene, Vita ^a   Kazlauskaite, Nijole ^a   Danilevičiüte, Vita ^a   Mauricas, Mykolas ^a   Den Otter, Willem ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; CD57; CD8; Immunotherapy; Prediction; Review; Survival

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CALGRANULIN A; CANCER VACCINE; CD16 ANTIGEN; CD45RO ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CETUXIMAB; CISPLATIN; CYTOKINE; DACARBAZINE; FC RECEPTOR IIB; FLUOROPYRIMIDINE; IMMUNOGLOBULIN G; INTERLEUKIN 2; IRINOTECAN; MONOCLONAL ANTIBODY; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; TUBERCULIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BCG VACCINATION; BLADDER CANCER; BLADDER TUMOR; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DIAGNOSTIC VALUE; DONOR LYMPHOCYTE INFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; EX VIVO STUDY; FOLLICULAR LYMPHOMA; GENETIC POLYMORPHISM; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFER; MELANOMA; METASTASIS; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PREDICTIVE VALUE; PREMEDICATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 79953251447     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Stewart DJ and Kurzrock R: Cancer: the road to Amiens. J Clin Oncol 27: 328-333, 2009.
2. Marshall JL: Time to shift the focus of the war: it is not all about the enemy. J Clin Oncol 27: 168-169, 2009.
3. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H and Ohtani H: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132-5136, 2001. (Pubitemid 32681545)
4. Schumacher K, Haensch W, Röefzaad C and Schlag PM: Prognostic significance of activated CD8(+) T-cell infiltrations within esophageal carcinomas. Cancer Res 61: 3932-3936, 2001. (Pubitemid 32720953)
5. Ohtani H: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7: 4, 2007.
6. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ and Sato E: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 104: 3967-3972, 2007. (Pubitemid 47181562)
7. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S and Ochiai A: Predominant infiltration of macrophages and CD8(+) T-cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113: 1387-1395, 2008.
8. de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H and Nijman HW: Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114: 105-110, 2009.
9. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T and Nijman HW: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58: 449-459, 2009.
10. Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T and Katano M: Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 59: 653-661, 2010.
11. + tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 59: 1543-1549, 2010.
12. + T-cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol 90: 300-307, 1995.
13. Sze DM, Brown RD, Yuen E, Gibson J, Ho J, Raitakari M, Basten A, Joshua DE and Fazekas de St Groth B: Clonal cytotoxic T-cells in myeloma. Leuk Lymphoma 44: 1667-1674, 2003.
14. + lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22: 3679-3683, 2002.
15. Simon R: Moving from correlative science to predictive oncology. EPMA J 1: 377-387, 2010.
16. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM and Kaufman HL: Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27: 2645-2652, 2009.
17. Dudek AZ, Yee RT, Manivel JC, Isaksson R and Yee HO: Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Anticancer Res 30: 987-992, 2010.
18. Gajewski TF, Louahed J and Brichard VG: Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16: 399-403, 2010.
19. Kim YJ, Ha YS, Kim SK, Yoon HY, Lym MS, Kim MJ, Moon SK, Choi YH and Kim WJ: Gene signatures for the prediction of response to bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 16: 2131-2137, 2010.
20. Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC and Chopin DK: Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 43: 351-360, 2003.
21. Kirkwood JM and Tarhini AA: Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 27: 2583-2585, 2009.
22. Morales A, Eidinger D and Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976.
23. Böhle A: Bladder cancer: meta-analysis of BCG versus mitomycin C - A deeper insight? Nat Rev Urol 7: 8-10, 2010.
24. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L and Fradet Y: Bladder tumor-infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol 55: 1386-1395, 2009.
25. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985. (Pubitemid 16212345)
26. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van Der Meijden AP, Koten JW, Boon TA, Siedlar M and Zembala M: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159: 1183-1186, 1998.
27. Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CH, Koten JW, Battermann JJ and Den Otter W: Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 54: 792-798, 2005. (Pubitemid 40977147)
28. Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJE, Ziekman PGPM and Koten JW: Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57: 931-950, 2008.
29. McDermott DF and Atkins MB: Immunotherapy of metastatic renal cell carcinoma. Cancer J 14: 320-324, 2008.
30. Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B and Håkansson L: Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer 85: 1871-1877, 2001.
31. Donskov F and von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24: 1997-2005, 2006.
32. Jensen HK, Donskov F, Nordsmark M, Marcussen N and von der Maase H: Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 15: 1052-1058, 2009.
33. Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N and Morita T: Tumor-infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 27: 1137-1141, 2007. (Pubitemid 46587031)
34. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F and Nespoli A: Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26: 394-402, 2003. (Pubitemid 37128551)
35. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM and Keilholz U: Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 25: 1562-1569, 2007. (Pubitemid 46733083)
36. + subset. J Immunol 154: 6182-6190, 1995.
37. + lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus. J Immunol 155: 5046-5056, 1995. (Pubitemid 3010847)
38. + lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha. Anticancer Res 28: 1139-1142, 2008. (Pubitemid 351578851)
39. Elliott GT, McLeod RA, Perez J and Von Eschen KB: Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 9: 264-272, 1993. (Pubitemid 23154466)
40. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK and Armstrong CA: A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T-cell repertoire. Mol Med 4: 783-794, 1998. (Pubitemid 29180125)
41. + lymphocytes in bladder carcinoma patients after intravesical IL-2. Anticancer Res 31: 699-704, 2011.
42. Westermann J and Pabst R: Lymphocyte subsets in the blood: A diagnostic window on the lymphoid system? Immunol Today 11: 406-410, 1990.
43. Blum KS and Pabst R: Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 108: 45-51, 2007.
44. Reichert JM: Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9: 423-430, 2008.
45. Farag SS, Flinn IW, Modali R, Lehman TA, Young D and Byrd JC: Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103: 1472-1474, 2004. (Pubitemid 38168664)
46. O'Donovan N and Crown J: EGFR and HER-2 antagonists in breast cancer. Anticancer Res 27: 1285-1294, 2007. (Pubitemid 46813089)
47. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
48. Weng WK and Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947, 2003.
49. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P and Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758, 2002. (Pubitemid 34525533)
50. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM and Ardizzoni A: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796, 2008.
51. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC and Boissière-Michot F: Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-1129, 2009.
52. Amigorena S: Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med 195: F1-3, 2002.
53. Akiyama K, Ebihara S, Yada A, Matsumura K, Aiba S, Nukiwa T and Takai T: Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 170: 1641-1648, 2003. (Pubitemid 36197377)
54. + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13: 2714-2721, 2007. (Pubitemid 46788040)
55. + T-cell axis in patients with breast cancer. Br J Cancer 100: 1061-1067, 2009.
56. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL and Clynes R: Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13: 5133-5143, 2007. (Pubitemid 47502081)
57. Emens LA: Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 13: 295-308, 2008.
58. Chapman PB: Melanoma vaccines. Semin Oncol 34: 516-523, 2007.
59. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ and de Vries IJ: Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57: 1559-1568, 2008.
60. Wada J, Yamasaki A, Nagai S, Yanai K, Fuchino K, Kameda C, Tanaka H, Koga K, Nakashima H, Nakamura M, Tanaka M, Katano M and Morisaki T: Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients. Anticancer Res 28: 2401-2408, 2008.
61. Burgdorf SK, Claesson MH, Nielsen HJ and Rosenberg J: Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. Acta Oncol 48: 1157-64, 2009.
62. Schattenberg AV and Dolstra H: Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol 17: 617-621, 2005. (Pubitemid 41566418)
63. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L and Jones RJ: Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 12: 414-421, 2006. (Pubitemid 43380958)
64. Rosenberg SA and Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240, 2009.
65. Hodes RJ, Hathcock KS and Weng NP: Telomeres in T- and B-cells. Nat Rev Immunol 2: 699-706, 2002.
66. + cytotoxic T lymphocytes in HIV-infected patients. J Exp Med 200: 1407-1417, 2004. (Pubitemid 39657288)
67. Characiejus D, Hodzic J and Jacobs JJL: "First do no harm" and the importance of prediction in oncology. EPMA J 1: 369-375, 2010.
68. Yu P and Fu YX: Tumor-infiltrating T lymphocytes: Friends or foes? Lab Invest 86: 231-245, 2006.
69. + T-cells and IFN-γ in establishing and maintaining the tumor-dormant state. J Immunol 162: 2842-2849, 1999. (Pubitemid 29309310)
70. + T lymphocytes and functional immune deficiency. J Leukoc Biol 87: 107-116, 2010.
71. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM and Weyand CM: Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 75: 12182-12187, 2001. (Pubitemid 33115891)
72. + T-cells. J Clin Invest 115: 1616-1626, 2005.
73. Karan D, Krieg AM and Lubaroff DM: Paradoxical enhancement of CD8 T-cell-dependent anti tumor protection despite reduced CD8 T-cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 121: 1520-1528, 2007. (Pubitemid 47328711)
74. Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM, Siegenbeek van Heukelom LH, Ossenkoppele GJ and Oudejans JJ: Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 18: 589-596, 2004. (Pubitemid 38425875)
75. + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 89: 3700-3707, 1997.